Maurits Janssen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Maurits janssen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Maurits Janssen Today - Breaking & Trending Today

Lonza and Moderna enter agreement to increase vaccine production


Article by Amanda Doyle
LONZA has entered a new agreement with Moderna to double production for Moderna’s Covid-19 vaccine at its site in Switzerland.
Lonza and Moderna first started working together in May 2020 with a ten-year strategic collaboration agreement for the large-scale manufacture of Moderna’s mRNA Covid-19 vaccine and additional Moderna products in the future. They have now entered into a new agreement for Lonza to increase production of the key mRNA active ingredient used in the Moderna vaccine.
Three additional manufacturing lines will be installed at Lonza’s Visp site in Switzerland, which will double production at the site. The new lines are expected to be operational in early 2022. ....

Pierre Alain Ruffieux , Moderna Covid , Maurits Janssen , Lonza Visp , Strategic Business Development Small Molecules At Lonza , Alain Ruffieux , Strategic Business Development Small Molecules , மௌரீட்ஸ் ஜான்சன் , மூலோபாய வணிக வளர்ச்சி சிறிய மூலக்கூறுகள் ,

Lonza Group AG: Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp


Lonza Group AG: Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp
Lonza will invest CHF 200 million to construct a new manufacturing complex
The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules
The investment is supported by a long-term collaboration and capital contribution with a major biopharmaceutical partner
The new manufacturing complex is designed to accommodate future small molecule expansions
Quote from Maurits Janssen, Strategic Business Development Small Molecules, Lonza:
Supply is critical for our global partner in the oncology field. With this investment, we are enabling the treatment of many cancer patients. Oncology continues to be the leading indication in biopharma and a key driver for highly potent ingredients such as antibody-drug conjugates. In addition, small molecule oncology therapies require specific technologies. These challenges were ....

Switzerland General , Martina Ribar Hestericov , Dirk Oehlers , Maurits Janssen , Gordon Bates , Head Of External Communications , Lonza Group Ltd , Strategic Business Development Small Molecules , Singapore Exchange Securities Trading Limited , Swiss Exchange , Lonza Announces Construction , New Small Molecule Manufacturing Complex , Small Molecules , Swiss Alps , Antibody Drug Conjugates , Antibody Drug Conjugate , Group Ltd , சுவிட்சர்லாந்து ஜநரல் , மௌரீட்ஸ் ஜான்சன் , கோர்டந் பேட்ஸ் , தலை ஆஃப் வெளிப்புறம் தகவல்தொடர்புகள் , மூலோபாய வணிக வளர்ச்சி சிறிய மூலக்கூறுகள் , சிங்கப்பூர் பரிமாற்றம் பத்திரங்கள் வர்த்தக வரையறுக்கப்பட்டவை , சுவிஸ் பரிமாற்றம் , சிறிய மூலக்கூறுகள் , சுவிஸ் ஆல்ப்ஸ் ,